Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Role of properdin in complement-mediated kidney diseases.

van Essen MF, Ruben JM, de Vries APJ, van Kooten C; COMBAT consortium .

Nephrol Dial Transplant. 2019 May 1;34(5):742-750. doi: 10.1093/ndt/gfy233.

PMID:
30053164
2.

Human plasmacytoid dendritic cells acquire phagocytic capacity by TLR9 ligation in the presence of soluble factors produced by renal epithelial cells.

Ruben JM, García-Romo GS, Breman E, van der Kooij S, Redeker A, Arens R, van Kooten C.

Kidney Int. 2018 Feb;93(2):355-364. doi: 10.1016/j.kint.2017.08.006. Epub 2017 Oct 20.

PMID:
29061332
3.

Local delivery of liposomal prednisolone leads to an anti-inflammatory profile in renal ischaemia-reperfusion injury in the rat.

van Alem CMA, Boonstra M, Prins J, Bezhaeva T, van Essen MF, Ruben JM, Vahrmeijer AL, van der Veer EP, de Fijter JW, Reinders ME, Meijer O, Metselaar JM, van Kooten C, Rotmans JI.

Nephrol Dial Transplant. 2018 Jan 1;33(1):44-53. doi: 10.1093/ndt/gfx204.

PMID:
28992069
4.

Primary Human Renal-Derived Tubular Epithelial Cells Fail to Recognize and Suppress BK Virus Infection.

de Kort H, Heutinck KM, Ruben JM, Ede V Silva A, Wolthers KC, Hamann J, Ten Berge IJM.

Transplantation. 2017 Aug;101(8):1820-1829. doi: 10.1097/TP.0000000000001521.

PMID:
27755502
5.

Uptake of HLA Alloantigens via CD89 and CD206 Does Not Enhance Antigen Presentation by Indirect Allorecognition.

Breman E, Ruben JM, Franken KL, Heemskerk MH, Roelen DL, Claas FH, van Kooten C.

J Immunol Res. 2016;2016:4215684. doi: 10.1155/2016/4215684. Epub 2016 Jun 20.

6.

A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation.

Ruben JM, Visser LL, Heinhuis KM, O'Toole T, Bontkes HJ, Westers TM, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

PLoS One. 2015 Aug 7;10(8):e0135219. doi: 10.1371/journal.pone.0135219. eCollection 2015.

7.

Differential capacity of human interleukin-4 and interferon-α monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen.

Ruben JM, Bontkes HJ, Westers TM, Hooijberg E, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

Cancer Immunol Immunother. 2015 Nov;64(11):1419-27. doi: 10.1007/s00262-015-1741-1. Epub 2015 Jul 28.

8.

In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity.

Ruben JM, Bontkes HJ, Westers TM, Hooijberg E, Ossenkoppele GJ, van de Loosdrecht AA, de Gruijl TD.

Oncoimmunology. 2014 Jul 3;3(7):e946360. eCollection 2014.

9.

CD1d-restricted antigen presentation by Vγ9Vδ2-T cells requires trogocytosis.

Schneiders FL, Prodöhl J, Ruben JM, O'Toole T, Scheper RJ, Bonneville M, Scotet E, Verheul HM, de Gruijl TD, van der Vliet HJ.

Cancer Immunol Res. 2014 Aug;2(8):732-40. doi: 10.1158/2326-6066.CIR-13-0167. Epub 2014 Apr 21.

10.

Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines.

Ruben JM, van den Ancker W, Bontkes HJ, Westers TM, Hooijberg E, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

Cancer Immunol Immunother. 2014 Apr;63(4):335-45. doi: 10.1007/s00262-013-1515-6. Epub 2014 Jan 3.

PMID:
24384837
11.

Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy.

van den Ancker W, Wijnands PG, Ruben JM, Westers TM, Punt B, Bachas C, Ravenshorst N, van Wetering S, Kruisbeek AM, Bontkes HJ, Ossenkoppele GJ, van de Loosdrecht AA, de Gruijl TD.

Immunotherapy. 2013 Nov;5(11):1183-90. doi: 10.2217/imt.13.125.

PMID:
24188673
12.

Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines.

Ruben JM, Visser LL, Bontkes HJ, Westers TM, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

Immunotherapy. 2013 Aug;5(8):859-68. doi: 10.2217/imt.13.76. Review.

PMID:
23902555
13.

Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy.

van den Ancker W, Ruben JM, Westers TM, Wulandari D, Bontkes HJ, Hooijberg E, Stam AG, Santegoets SJ, Ossenkoppele GJ, de Gruijl T, van de Loosdrecht A.

Oncoimmunology. 2013 Apr 1;2(4):e23971.

14.

Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes.

Bontkes HJ, Ruben JM, Alhan C, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA.

Leuk Res. 2012 Jul;36(7):921-30. doi: 10.1016/j.leukres.2012.03.026. Epub 2012 Apr 14.

15.

Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.

van den Ancker W, van Luijn MM, Ruben JM, Westers TM, Bontkes HJ, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

Cancer Immunol Immunother. 2011 Jan;60(1):37-47. doi: 10.1007/s00262-010-0917-y. Epub 2010 Sep 22.

16.

Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.

van den Ancker W, van Luijn MM, Westers TM, Bontkes HJ, Ruben JM, de Gruijl TD, Ossenkoppele GJ, van de Loosdrecht AA.

Immunotherapy. 2010 Jan;2(1):69-83. doi: 10.2217/imt.09.85. Review.

PMID:
20635890
17.

Addison's disease in a puppy.

Ruben JM, Walker MJ, Longstaffe JA.

Vet Rec. 1985 Jan 26;116(4):91-3.

PMID:
3976152
18.

Neurofibrosarcoma in a 19-year-old cat.

Ruben JM.

Vet Rec. 1983 Aug 6;113(6):135. No abstract available.

PMID:
6612976
19.

Key-Gaskell syndrome.

Ruben JM.

Vet Rec. 1983 Feb 12;112(7):159. No abstract available.

PMID:
6682588
20.

Surgical removal of a foreign body from the bovine oesophagus.

Ruben JM.

Vet Rec. 1977 Mar 12;100(11):220. No abstract available.

PMID:
855150

Supplemental Content

Loading ...
Support Center